H
Hassan Javanbakht
Researcher at Hoffmann-La Roche
Publications - 53
Citations - 3782
Hassan Javanbakht is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Hepatitis B virus & HBsAg. The author has an hindex of 27, co-authored 53 publications receiving 3460 citations. Previous affiliations of Hassan Javanbakht include Harvard University & La Roche College.
Papers
More filters
Journal ArticleDOI
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor
Matthew Stremlau,Michel Perron,Mark Lee,Yuan Li,Byeongwoon Song,Hassan Javanbakht,Felipe Diaz-Griffero,Donovan J. Anderson,Wesley I. Sundquist,Joseph Sodroski +9 more
TL;DR: It is demonstrated that TRIM5alpha variants from Old World monkeys specifically associate with the HIV type 1 (HIV-1) capsid and that this interaction depends on the TRIM 5alpha B30.2 domain.
Journal ArticleDOI
Retrovirus Restriction by TRIM5α Variants from Old World and New World Primates
Byeongwoon Song,Hassan Javanbakht,Michel Perron,Do Hyun Park,Matthew Stremlau,Joseph Sodroski +5 more
TL;DR: Variation in TRIM5α proteins among primate species accounts for the observed patterns of postentry restrictions in cells from these animals.
Journal ArticleDOI
The B30.2(SPRY) Domain of the Retroviral Restriction Factor TRIM5α Exhibits Lineage-Specific Length and Sequence Variation in Primates
Byeongwoon Song,Bert Gold,Colm O'hUigin,Hassan Javanbakht,Xing Li,Matthew Stremlau,Cheryl A. Winkler,Michael Dean,Joseph Sodroski +8 more
TL;DR: The results suggest that occasional, complex changes were incorporated into the TRIM5α B30.2 domain at discrete time points during the evolution of primates, based on the appearance of particular endogenous retroviruses in primate genomes.
Journal ArticleDOI
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Edward M. Kennedy,Leda Bassit,Henrik Mueller,Anand V.R. Kornepati,Hal P. Bogerd,Ting Nie,Payel Chatterjee,Hassan Javanbakht,Raymond F. Schinazi,Bryan R. Cullen +9 more
TL;DR: Together, these data provide proof of principle for the hypothesis that CRISPR/Cas systems have the potential to serve as effective tools for the depletion of the cccDNA pool in chronically HBV infected individuals.
Journal ArticleDOI
A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients
Nguyet Minh Nguyen,Chau Nguyen Bich Tran,Lam Khanh Phung,Kien Thi Hue Duong,Huy Le Anh Huynh,Jeremy Farrar,Quyen Nguyen,Hien Tinh Tran,Chau Van Vinh Nguyen,Laura Merson,Long T. Hoang,Martin L. Hibberd,Pauline P. K. Aw,Andreas Wilm,Niranjan Nagarajan,Dung Thi Nguyen,Mai Phuong Pham,Truong Thanh Nguyen,Hassan Javanbakht,Klaus Klumpp,Janet Hammond,Rosemary Petric,Marcel Wolbers,Chinh Nguyen,Cameron P. Simmons +24 more
TL;DR: Although this trial, the first of its kind in dengue, does not support balapiravir as a candidate drug, it does establish a framework for antiviral treatment trials in d Dengue and provides the field with a clinically evaluated benchmark molecule.